Abstract 98P
Background
Cell-free DNA (cfDNA) consists of circulating DNA fragments originating from cells throughout the body. It can be found in plasma and urine and is under heavy investigation for its potential to detect cancer both early, and as a minimally invasive biopsy. DNA methylation is strongly associated with tissue and cell type, and in the context of cancer, it is often significantly altered. Tumour derived cfDNA has been shown to contain tumour specific methylation patterns. In this study, we attempt to correlate tissue specific methylation with cfDNA methylation.
Methods
We extracted tumour tissue specific methylation signals from The Cancer Genome Association (TCGA) methylation data and used our RenovaroCube (AI platform) to mine tumour specific CpG sites from Illumina methylation array data. As Illumina methylation array data for liquid biopsies is scarce due to the high input requirements, we investigated an alternative methylation detection method: cell-free Methylation DNA ImmunoPrecipiation (cfMeDIP-seq). cfMeDIP-seq captures solely 5mC methylated cfDNA fragments, which are then sorted into 300bp windows. From 97 publicly available cfDNA plasma cfMeDIP samples (24 control, 23 CRC, 25 lung cancer, 25 BRCA) we extracted the 300bp windows containing mined TCGA CpG sites. Using random forest classifiers, we performed leave-one-out-cross-validations (LOOCV) for the classifcation of cancer types. We further validated the lung cancer model using a cfMeDIP-seq validation set (62 control, 55 lung cancer).
Results
From the TCGA data, we mined 86 NSCLC, 95 BRCA and 139 CRC specific CpG sites, resulting in 72, 74 and 121 300bp panels, respectively. The performance of the panels was evaluated through LOOCV, resulting in (Specificity/Sensitivity/Accuracy): NSCLC model: 0.96/0.59/0.75, BRCA model: 1.00/0.72/0.86, CRC model: 1.00/0.841/0.92. In the validation lung cancer dataset, we obtained a performance of 0.97/0.49/0.74.
Conclusions
It is possible to detect tissue specific methylation levels extracted from methylation array data using RenovaroCube platform in cfDNA using cfMeDIP-seq data.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
1792P - Molecular characterization from IMfirst: Atezolizumab plus chemotherapy in extensive-stage small cell lung cancer (ES-SCLC) in Spain
Presenter: Manuel Cobo Dols
Session: Poster session 07
1793P - Treatment and outcomes of limited disease small cell lung cancer (LD-SCLC) in the Canadian small cell lung cancer database (CASCADE)
Presenter: Sara Moore
Session: Poster session 07
1794P - Deciphering ERBB2-driven mechanisms that regulate tumor immune evasion and metastasis in SCLC
Presenter: Lydia Meder
Session: Poster session 07
1795P - Consolidation serplulimab following concurrent hypofractionated chemoradiotherapy for limited-stage SCLC: Preliminary analysis of phase II ASTRUM-LC01 study
Presenter: Yuqi Wu
Session: Poster session 07
1796P - Smoking-related genomic mutation patterns in patients with small cell lung cancer treated in ASTRUM-005 study
Presenter: Ying Cheng
Session: Poster session 07
1798P - Relapsed and refractory systemic therapy real-world outcomes in the Canadian small cell lung cancer database (CASCADE)
Presenter: Sara Moore
Session: Poster session 07
1799P - Efficacy and safety of integrating consolidative thoracic radiotherapy with immunochemotherapy in ES-SCLC: A real-world retrospective analysis
Presenter: Qi Zhang
Session: Poster session 07
1800P - Breaking chemo-immunotherapy resistance in SCLC-patient derived tumor with novel DDRi combinations
Presenter: Carminia Della Corte
Session: Poster session 07
1801P - Expression analysis of Fuc-GM1 ganglioside in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) with BMS-986012, nivolumab, and carboplatin-etoposide
Presenter: Kenneth O'Byrne
Session: Poster session 07